Comparative Pharmacology
Head-to-head clinical analysis: BROMSITE versus PROLENSA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMSITE versus PROLENSA.
BROMSITE vs PROLENSA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bromsite (bromfenac ophthalmic solution) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) 1 and 2, thereby reducing prostaglandin synthesis in ocular tissues.
Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and thereby decreasing inflammation, pain, and angiogenesis in the eye.
1-2 tablets (200-400 mg) orally 3-4 times daily as needed.
Adults: 1 drop in affected eye(s) twice daily (morning and evening) for 2 weeks.
None Documented
None Documented
Terminal elimination half-life 12–15 hours; prolonged in renal impairment (up to 30 hours).
Terminal elimination half-life is approximately 1.5 hours for the ocular route; after systemic absorption, half-life is about 4.5 hours. The short half-life limits systemic exposure but requires multiple daily dosing for sustained ocular effect.
Primarily renal excretion of unchanged drug (~70%) and glucuronide conjugate (~20%); minor biliary/fecal elimination (~10%).
Primarily renal elimination (approximately 70% of the dose as unchanged drug and metabolites), with the remainder excreted in feces via biliary secretion (approximately 30%).
Category C
Category C
Ophthalmic NSAID
Ophthalmic NSAID